Bearing “Edo” in Its Name, Japan-Originated Edoxaban Set to Challenge Rival Anticoagulants in World Market

The results of ENGAGE AF-TIMI 48, a PIII clinical trial of Daiichi Sankyo’s direct Factor Xa inhibitor edoxaban (brand name: Lixiana), were presented at a late-breaking clinical trial session of the American Heart Association (AHA) Scientific Sessions 2013 on November...read more